AstraZeneca aktie (AZN) | Pressmeddelande

Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three yea...

Cision • 18 Nov 08:00

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Cision • 12 Nov 08:10

Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial

Results demonstrated reduction in tumour volume, building on established safety and efficacy profile of Koselugo in children and supporting ...

Cision • 12 Nov 08:05

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

AstraZeneca and Daiichi Sankyo’s new application is based on the TROPION-Lung05 Phase II trial and supported by data from additional trials ...

Cision • 12 Nov 08:01

Resultatrapport för årets första nio månader samt tredje kvartalet 2024

Cision • 12 Nov 08:00

Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compa...

Cision • 08 Nov 08:00

AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024

First results from AMPLIFY trial will reinforce Calquence as leading second-generation BTK inhibitor in frontline chronic lymphocytic leukae...

Cision • 07 Nov 08:00

AZN share price movement

Cision • 05 Nov 18:08

AstraZeneca China President currently under investigation

Cision • 30 Oct 14:00

Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taki...

Cision • 28 Oct 08:00

Wainzua (eplontersen) recommended for approval in the EU by CHMP for the treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Recommendation based on NEURO-TTRansform Phase III results showing Wainzua demonstrated consistent and sustained benefit improving neuropath...

Cision • 21 Oct 08:00

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumo...

Cision • 16 Oct 09:30

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer

Approval based on DESTINY-Lung02 and DESTINY-Lung05 results which showed Enhertu demonstrated clinically meaningful efficacy in previously t...

Cision • 14 Oct 09:45

Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care

Clinical and real-world data will reinforce the long-term safety and efficacy profiles of Ultomiris and Soliris and highlight the potential ...

Cision • 10 Oct 08:01

Rättelse: AstraZeneca i Södertälje utsett till Global Lighthouse av World Economic Forum

Två av AstraZenecas globala och mest avancerade tillverkningsanläggningar för läkemedel, i Södertälje och i Wuxi, Kina, har idag blivit utse...

Cision • 08 Oct 11:34

AstraZeneca i Södertälje utsett till Global Lighthouse av World Economic Forum

Två av AstraZenecas globala och mest avancerade tillverkningsanläggningar för läkemedel, i Södertälje och i Wuxi, Kina, har idag blivit utse...

Cision • 08 Oct 10:46

AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy

Cision • 07 Oct 10:30

Airsupra demonstrated statistically significant and clinically meaningful reduction in risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

Airsupra demonstrated statistically significant and clinically meaningful reduction in risk of severe exacerbations in patients with intermi...

Cision • 07 Oct 08:07

Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma

Cision • 03 Oct 08:02

Enhertu granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

Enhertu granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least on...

Cision • 01 Oct 08:02

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Cision • 26 Sep 08:02

Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis

Cision • 23 Sep 08:07

Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer i...

Cision • 23 Sep 08:02

FluMist approved for self-administration in the US

Cision • 20 Sep 19:02

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

Cision • 18 Sep 08:01

Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial

Longest survival follow-up ever reported for a Phase III immunotherapy trial in this setting.

Cision • 16 Sep 08:30

Imfinzi perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial

First immunotherapy regimen before and after surgery to demonstrate statistically significant and clinically meaningful overall survival imp...

Cision • 15 Sep 16:35

Enhertu showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases

AstraZeneca and Daiichi Sankyo’s Enhertu achieved a 61.

Cision • 13 Sep 16:07

Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

Datopotamab deruxtecan showed median overall survival of 14.

Cision • 09 Sep 19:52

AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential

AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-...

Cision • 09 Sep 08:02

Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan demonstrated meaningfully greater magnitude of progression-free survival benefit in ...

Cision • 08 Sep 18:25

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024

Cision • 03 Sep 08:02

AstraZeneca Sverige uppnår hållbarhetsmål – 98 procents minskning av växthusgasutsläpp sedan 2015

Cision • 29 Aug 15:00

AstraZeneca investerar i utbyggnad av Sweden Biomanufacturing Center i Södertälje

AstraZeneca, ett globalt ledande företag inom bioläkemedel, gör en tilläggsinvestering på 135 miljoner dollar (motsvarande 1 475 miljoner SE...

Cision • 26 Aug 14:00

Fasenra approved in China for the treatment of severe eosinophilic asthma

Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improv...

Cision • 20 Aug 08:02

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs.

Cision • 16 Aug 08:01

Imfinzi granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US

Based on ADRIATIC Phase III trial which demonstrated statistically significant and clinically meaningful overall survival and progression-fr...

Cision • 15 Aug 08:00

Lynparza and combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer

First immunotherapy and PARP inhibitor combination approved in endometrial cancer.

Cision • 14 Aug 08:00

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Approval based on DESTINY-Gastric06 results which showed Enhertu demonstrated clinically meaningful efficacy in this setting.

Cision • 13 Aug 11:15

Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial

Favourable trend in overall survival was also observed

Cision • 29 Jul 08:02

FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results

Cision • 26 Jul 08:00

Resultat för första halvåret samt andra kvartalet 2024

Cision • 25 Jul 08:00

Acquisition of Amolyt Pharma completed

Cision • 15 Jul 08:01

Tagrisso with the addition of chemotherapy approved in the EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs.

Cision • 05 Jul 08:01

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COV...

Cision • 01 Jul 08:06

Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer

Imfinzi also recommended for patients with mismatch repair deficient disease.

Cision • 01 Jul 08:01

Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by nearly half vs...

Cision • 26 Jun 08:01

Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs.

Cision • 25 Jun 08:10

Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer

Cision • 25 Jun 08:10

Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

First immunotherapy regimen before and after surgery to extend survival in bladder cancer.

Cision • 25 Jun 08:00

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

First and only AKT inhibitor approved in the EU for breast cancer patients with specific biomarker alterations (PIK3CA, AKT1 or PTEN).

Cision • 20 Jun 08:00

Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer

Cision • 18 Jun 08:00

Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs.

Cision • 17 Jun 08:00

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

First and only BTK inhibitor to demonstrate favourable overall survival trend vs.

Cision • 17 Jun 07:55

Farxiga approved in the US for the treatment of paediatric type-2 diabetes

US patients aged 10 years and older can now benefit from Farxiga for type-2 diabetes.

Cision • 12 Jun 21:01

Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Decision based on LAURA Phase III trial results which extended median progression-free survival by more than three years.

Cision • 10 Jun 08:01

Acquisition of Fusion completed

Cision • 04 Jun 22:05

Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer

Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months...

Cision • 03 Jun 08:00

Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than ...

Cision • 03 Jun 07:55

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

57% of patients treated with Imfinzi were alive at three years in ADRIATIC Phase III trial.

Cision • 03 Jun 07:50

Enhertu demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

DESTINY-Breast06 results show AstraZeneca and Daiichi Sankyo’s Enhertu is the first HER2-directed medicine and ADC to demonstrate clinically...

Cision • 03 Jun 07:45

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

In the overall trial population, survival results numerically favoured AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan but did not r...

Cision • 27 May 08:02

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung can...

Cision • 22 May 08:02

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Launch of 20 new medicines expected by 2030. Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Cision • 21 May 08:02

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs.

Cision • 20 May 08:00

SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population

SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient popul...

Cision • 16 May 08:01

AstraZeneca completes equity investment agreement with Cellectis

Cision • 06 May 08:01

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD.

Cision • 02 May 08:05

Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

First BTK inhibitor to show favourable trend in overall survival vs.

Cision • 02 May 08:01

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50% vs...

Cision • 29 Apr 08:06

Enhertu improved PFS in HER2-low and ultralow

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low m...

Cision • 29 Apr 08:01

Resultat första kvartalet 2024

Cision • 25 Apr 08:00

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and redu...

Cision • 23 Apr 08:00

AstraZeneca advances the science of infectious disease protection at ECCMID 2024

Real-world effectiveness data on Beyfortus reinforce the impact of passive immunisation protecting infants from RSV hospitalisation.

Cision • 17 Apr 09:01

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

Longest survival follow-up ever reported for immunotherapy treatment in this setting.

Cision • 16 Apr 08:02

AstraZeneca increases 2024 dividend by 7%

Cision • 11 Apr 08:00

Alexion data at AAN 2024 demonstrate how Ultomiris and Soliris can transform outcomes for rare neurological diseases

New findings from CHAMPION-NMOSD trial will reinforce the potential for Ultomiris to eliminate relapses and improve care in AQP4 Ab+ NMOSD.

Cision • 08 Apr 08:03

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s Enhertu which showed clinically meaningful responses across a broad range...

Cision • 08 Apr 08:00

Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial.

Cision • 05 Apr 08:01

Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH

Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial.

Cision • 02 Apr 08:06

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Application based on results from the TROPION-Breast01 Phase III trial.

Cision • 02 Apr 08:01

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

Cision • 27 Mar 08:07

Beyfortus approved in Japan for the prevention of RSV disease in infants

Cision • 27 Mar 08:02

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

Cision • 25 Mar 08:03

Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial

Combination shows consistent benefit across prespecified post-progression outcomes.

Cision • 21 Mar 15:11

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Cision • 19 Mar 08:02

Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with pMMR advanced or recurrent endometrial cancer

Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs.

Cision • 18 Mar 13:08

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

Cision • 14 Mar 08:02

Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer

Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive...

Cision • 04 Mar 08:02

Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia

Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual ha...

Cision • 26 Feb 08:01

Acquisition of Gracell completed

Cision • 22 Feb 14:16

Acquisition of Icosavax Completed

Cision • 19 Feb 16:01

Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs.

Cision • 19 Feb 08:11

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small ...

Cision • 19 Feb 08:07

Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III tr...

Cision • 19 Feb 08:02

Resultat för helåret samt fjärde kvartalet 2023

Cision • 08 Feb 08:00

Positive high-level results from Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency with global ATTRibute-CM Phase III trial

Positive high-level results from Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...

Cision • 02 Feb 08:02

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

Cision • 29 Jan 08:02

Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation

Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs.

Cision • 19 Jan 16:02

Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy

Cision • 19 Jan 08:02

Börskollen

För dig med koll på börsen

Pressmeddelanden från AstraZeneca

Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Resultatrapport för årets första nio månader samt tredje kvartalet 2024

Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024

AZN share price movement

AstraZeneca China President currently under investigation

Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis

Wainzua (eplontersen) recommended for approval in the EU by CHMP for the treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer

Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care

Rättelse: AstraZeneca i Södertälje utsett till Global Lighthouse av World Economic Forum

AstraZeneca i Södertälje utsett till Global Lighthouse av World Economic Forum

AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy

Airsupra demonstrated statistically significant and clinically meaningful reduction in risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma

Enhertu granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis

Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

FluMist approved for self-administration in the US

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial

Imfinzi perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial

Enhertu showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases

Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential

Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024

AstraZeneca Sverige uppnår hållbarhetsmål – 98 procents minskning av växthusgasutsläpp sedan 2015

AstraZeneca investerar i utbyggnad av Sweden Biomanufacturing Center i Södertälje

Fasenra approved in China for the treatment of severe eosinophilic asthma

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery

Imfinzi granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US

Lynparza and combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial

FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results

Resultat för första halvåret samt andra kvartalet 2024

Acquisition of Amolyt Pharma completed

Tagrisso with the addition of chemotherapy approved in the EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer

Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer

Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer

Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

Farxiga approved in the US for the treatment of paediatric type-2 diabetes

Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Acquisition of Fusion completed

Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer

Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

Enhertu demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore

SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population

AstraZeneca completes equity investment agreement with Cellectis

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

Enhertu improved PFS in HER2-low and ultralow

Resultat första kvartalet 2024

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

AstraZeneca advances the science of infectious disease protection at ECCMID 2024

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

AstraZeneca increases 2024 dividend by 7%

Alexion data at AAN 2024 demonstrate how Ultomiris and Soliris can transform outcomes for rare neurological diseases